Galmed Pharmaceuticals (NASDAQ:GLMD) Given Market Perform Rating at Roth Capital

Roth Capital reaffirmed their market perform rating on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report issued on Sunday morning, AnalystRatings.com reports. The firm currently has a $33.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. Maxim Group started coverage on Galmed Pharmaceuticals in a research note on Friday, May 15th. They set a buy rating and a $10.00 price target for the company. Cantor Fitzgerald reissued an overweight rating and set a $14.00 price target on shares of Galmed Pharmaceuticals in a research note on Sunday. Raymond James dropped their price target on Galmed Pharmaceuticals from $25.00 to $20.00 and set an outperform rating for the company in a research note on Friday, May 15th. HC Wainwright dropped their price target on Galmed Pharmaceuticals from $34.00 to $29.00 and set a buy rating for the company in a research note on Friday, May 15th. Finally, ValuEngine lowered Galmed Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Tuesday, April 7th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Galmed Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $18.78.

NASDAQ:GLMD opened at $4.72 on Friday. Galmed Pharmaceuticals has a 12-month low of $3.02 and a 12-month high of $7.38. The stock has a 50-day moving average price of $4.99 and a 200 day moving average price of $5.01. The stock has a market capitalization of $94.57 million, a P/E ratio of -4.33 and a beta of 2.51.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its earnings results on Thursday, May 14th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. Research analysts predict that Galmed Pharmaceuticals will post -1.28 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Phoenix Holdings Ltd. raised its holdings in shares of Galmed Pharmaceuticals by 312.9% in the first quarter. Phoenix Holdings Ltd. now owns 75,383 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 57,128 shares during the period. Vivo Capital LLC purchased a new stake in shares of Galmed Pharmaceuticals in the first quarter worth approximately $2,976,000. Squarepoint Ops LLC raised its holdings in shares of Galmed Pharmaceuticals by 238.9% in the first quarter. Squarepoint Ops LLC now owns 34,350 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 24,215 shares during the period. Voss Capital LLC raised its holdings in shares of Galmed Pharmaceuticals by 5.9% in the first quarter. Voss Capital LLC now owns 159,454 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 8,939 shares during the period. Finally, Morgan Stanley increased its holdings in Galmed Pharmaceuticals by 24.6% during the 1st quarter. Morgan Stanley now owns 77,552 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 15,322 shares during the period. Hedge funds and other institutional investors own 33.85% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

See Also: Does the discount rate affect the economy?

Analyst Recommendations for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.